Hot Features
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailabl... BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.2 | -13.4078212291 | 8.95 | 8.95 | 7.63 | 179514 | 8.12110102 | CS |
| 4 | -0.1 | -1.27388535032 | 7.85 | 9.26 | 7.6 | 381363 | 8.50903359 | CS |
| 12 | -1.5 | -16.2162162162 | 9.25 | 9.73 | 7.6 | 356585 | 8.73049079 | CS |
| 26 | -6.11 | -44.0836940837 | 13.86 | 14.87 | 7.6 | 306923 | 10.00157313 | CS |
| 52 | -1.9 | -19.689119171 | 9.65 | 14.87 | 7.6 | 276976 | 10.43670993 | CS |
| 156 | -1.9 | -19.689119171 | 9.65 | 14.87 | 7.6 | 276976 | 10.43670993 | CS |
| 260 | -1.9 | -19.689119171 | 9.65 | 14.87 | 7.6 | 276976 | 10.43670993 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.